Advair
Mylan’s Wixela becomes first FDA-approved generic version of GSK’s Advair inhaler
January 31, 2019Sales and Marketing Advair, COPD, FDA, Wixela, asthma, generic, pharma
Mylan’s Wixela has become the first generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhaler to …
FDA knocks back Mylan’s Advair generic for second time
June 14, 2018Sales and Marketing Advair, FDA, GSK, Mylan, pharma
The FDA has rejected Mylan’s generic version of GlaxoSmithKline’s Advair for the second time following its knockback last year, citing …
Hikma’s Advair generic delayed in the US
March 12, 2018Sales and Marketing Advair, FDA, GSK, GlaxoSmithKline, pharma
Hikma Pharmaceuticals has been knocked back with the news that the FDA has delayed approval of its generic lung treatment …
Teva launches competitors to GSK’s Advair inhaler
April 21, 2017Medical Communications, Sales and Marketing Advair, AirDuo, GSK, Teva, asthma
GSK has been anticipating competition to its Advair for two years and Teva has announced that it will be the …
Mylan’s generic of best-selling GSK drug delayed by FDA
March 30, 2017Sales and Marketing Advair, GSK, Mylan
Mylan’s plan to bring its generic competitor to GSK’s best-selling respiratory drug, Advair, has hit a major snag after it …
GSK and Theravance see FDA nod for asthma indication
March 20, 2015Sales and Marketing Advair, AstraZeneca, Dulera, FDA, Foradil, GSK, Merck, Symbicort, Theravance, asthma, breo, budesonide/formoterol fumarate dihydratem, ellipta, fluticasone propionate, formoterol fumarate, mometasone/formoterol
An FDA panel has recommended the approval of asthma treatment Breo Ellipta in adults – but voted against supporting its …
GSK blames respiratory woes as sales drop
February 5, 2015Sales and Marketing Advair, GSK, GlaxoSmithKline, HIV, ViiV, Witty, anoro ellipta, breo, lovaza, q4, sales
GlaxoSmithKline’s respiratory business has been flagged as the key factor in the firm’s fourth quarter financial misfortunes, as its total …
GSK confirms hundreds of US job cuts
December 3, 2014Medical Communications, Research and Development, Sales and Marketing Advair, GSK, Parexel, RTP, anoro, breo, job cuts, respiratory
GlaxoSmithKline has finally confirmed the rumours that it is cutting hundreds of US jobs as the UK firm struggles to …
GSK mulls $27 billion ViiV sell-off
October 23, 2014Medical Communications, Sales and Marketing AIDS, Advair, GSK, HIV, Pfizer, Q3, Shionogi, Tivicay, ViiV
After a difficult few years and another poor quarter, GlaxoSmithKline has announced that it is looking to float its fast-growing …
Boehringer’s Striverdi gains FDA approval
August 1, 2014Sales and Marketing Advair, COPD, Pfizer, Spiriva, asthma, olodaterol
Boehringer Ingelheim’s new lung drug Striverdi has gained US approval for patients with chronic obstructive pulmonary disorder. Striverdi Respimat (olodaterol), …
GSK sees profit fall
May 1, 2014Sales and Marketing Advair, China, GSK, Novartis, Q1, Seretide, Witty
GlaxoSmithKline has seen revenue and profit plummet in the first quarter of 2014. The UK-based company saw turnover fall 13% …
Almirall’s COPD drug launched in Europe
September 20, 2012Sales and Marketing Advair, Almirall, Eklira, Genuair, Seretide, Spiriva
Almirall has launched COPD treatment Eklira in Denmark following approval from the European Commission. Phase III trials demonstrated that Eklira …
GSK severe asthma drug progresses to Phase III
August 20, 2012Research and Development, Sales and Marketing Advair, GSK, Phase II, asthma, phase III
GlaxoSmithKline’s severe asthma drug mepolizumab has impressed in a mid-stage study, meaning it can now progress into Phase III testing. …
Underwhelming results for GSK’s Relovair
January 10, 2012Research and Development, Sales and Marketing Advair, COPD, GSK, Relovair, Seretide, asthma
GlaxoSmithKline says it is on track to file its respiratory drug Relovair in Europe and the US despite mixed results …
